{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:35:53Z","timestamp":1793381753154,"version":"4.5.0"},"reference-count":67,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,9,29]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate medication adherence, available social support and types of accessible support among patients with drug-sensitive tuberculosis (DS-TB). Coping mechanism(s) in TB management and associations between accessible support(s) and medication adherence were also explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Prospective questionnaire-guided cross-sectional study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings<\/jats:title>\n                    <jats:p>The WHO-certified TB directly observed therapy (DOT) clinic of two tertiary hospitals in Ibadan, southwest Nigeria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Adult patients with DS-TB attending the TB-DOT clinic of the hospitals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Primary outcomes were level of adherence to TB regimens, available social support and type(s) of accessible support. Secondary outcomes were coping mechanisms in TB management, as well as associations between accessible support(s) and medication adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 152 (89.4%) had optimal adherence. Available social supports were ranked as family (168; 98.8%) &gt;healthcare providers (166; 97.6%) &gt;government (119; 70.0%) &gt;non-governmental organisation (NGO) (118; 69.4%) &gt;religious affiliations (81; 47.6%) &gt;friends (65; 38.2%) &gt;patient association (3; 1.8%). Emotional (168; 98.8%) and financial (137; 80.6%) supports were mostly accessible from family, while drug support (118; 69.4%) was largely received from NGO. Seeking emotional support from family or friends (159; 93.5%) was the most effective coping mechanism. Medication adherence was higher among patients who received health information (p=0.02) and drug support (p=0.03) from the NGO. There was no difference in medication adherence of patients with or without emotional (p=0.20) and financial support (p=0.53) from family, as well as from friends (p=0.31\u2009and p&gt;0.99, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nearly ninety per cent of DS-TB patients had optimal adherence. Family was the most available source of social support for TB management, with one hundred and approximately eighty-two per cent respectively citing emotional and financial support as most accessible from the family. Emotional support from family or friends was the most effective coping mechanism in TB management. There is generally a need for initiation and implementation of an expanded social support system for DS-TB patients as a critical step towards achieving the WHO End-TB strategy milestone target.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-099559","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T09:17:53Z","timestamp":1760519873000},"page":"e099559","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment adherence, social support and coping mechanisms among patients with drug-sensitive tuberculosis: a cross-sectional study in two directly-observed therapy centres in southwest Nigeria"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0213-2723","authenticated-orcid":false,"given":"Rasaq","family":"Adisa","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration, University of Ibadan Faculty of Pharmacy, Ibadan, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah Mafolayomi","family":"Durojaye","sequence":"additional","affiliation":[{"name":"University of Ibadan, Ibadan, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2025120415064042000_15.10.e099559.1","unstructured":"World Health Organization . Sustainable development goals. 2024. Available: https:\/\/sdgs.un.org [accessed 15 Aug 2025]"},{"key":"2025120415064042000_15.10.e099559.2","unstructured":"World health organization . Global tuberculosis report 2024. Geneva, 2024."},{"key":"2025120415064042000_15.10.e099559.3","unstructured":"World Health Assembly . Global strategy and targets for tuberculosis prevention, care and control after 2015 (resolution wha67.1, agenda item 12.1). Geneva, 2014. Available: http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA67\/A67_R1-en.pdf [accessed 15 Aug 2025]"},{"key":"2025120415064042000_15.10.e099559.4","unstructured":"Resolution 78\/5: political declaration of the high-level meeting of the general assembly on the fight against tuberculosis. New York: United Nations, 2023. Available: https:\/\/undocs.org\/A\/RES\/78\/5 [accessed 15 Aug 2025]"},{"key":"2025120415064042000_15.10.e099559.5","unstructured":"World Health Organziation . Global tuberculosis report 2023. Geneva, 2023. Available: https:\/\/iris.who.int\/handle\/10665\/373828"},{"key":"2025120415064042000_15.10.e099559.6","unstructured":"World Health Organization . Tuberculosis data. Geneva, 2023. Available: https:\/\/www.who.int\/tb\/data\/en [accessed 15 Aug 2025]"},{"key":"2025120415064042000_15.10.e099559.7","doi-asserted-by":"crossref","first-page":"723","DOI":"10.5588\/ijtld.17.0835","article-title":"Global tuberculosis targets and milestones set for 2016-2035: definition and rationale","volume":"22","author":"Floyd","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025120415064042000_15.10.e099559.8","unstructured":"World Health Organization and the Ministry of Health of the Russian Federation . Moscow declaration to end tb; first who global ministerial conference on ending tb in the sustainable development era: a multisectoral response. Geneva, 2017. Available: https:\/\/iris.who.int\/handle\/10665\/345527 [accessed 15 Aug 2025]"},{"key":"2025120415064042000_15.10.e099559.9","unstructured":"Stop TB Partnership . The global plan to end tb, 2023\u20132030. Geneva, 2022. Available: https:\/\/www.stoptb.org\/global-plan-to-end-tb\/global-plan-to-end-tb-2023-2030 [accessed 15 Aug 2025]"},{"key":"2025120415064042000_15.10.e099559.10","unstructured":"World Health Organization . WHO global lists of high burden countries for tuberculosis (tb), tb\/hiv and multidrug\/ rifampicin-resistant tb (mdr\/rr-tb), 2021\u20132025: background document. Geneva, 2021. Available: https:\/\/apps.who.int\/iris\/handle\/10665\/341980 [accessed 15 Aug 2025]"},{"key":"2025120415064042000_15.10.e099559.11","unstructured":"Nigeria national tuberculosis and leprosy control program. Available: https:\/\/ntblcp.org.ng [Accessed 10 Aug 2025]."},{"key":"2025120415064042000_15.10.e099559.12","unstructured":"Nigeria tuberculosis roadmap overview. Fiscal Year; 2021. Available: https:\/\/www.usaid.gov\/sites [Accessed 10 Aug 2025]."},{"key":"2025120415064042000_15.10.e099559.13","unstructured":"World Health Organization . The latest who treatment guidelines (5) \u2013 who consolidated guidelines on tuberculosis. module 4: drug-susceptible tuberculosis treatment. Geneva, 2022. Available: https:\/\/iris.who.int\/handle\/10665\/353829 [accessed 15 Aug 2025]"},{"key":"2025120415064042000_15.10.e099559.14","unstructured":"World Health Organization . Guidelines for treatment of drug-susceptible tuberculosis and patient care: 2017 update. document who\/htm\/tb\/2017.05. Geneva, 2017."},{"key":"2025120415064042000_15.10.e099559.15","unstructured":"World Health Organization . Compendium of who guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis. document who\/htm\/tb\/2017.13. Geneva, 2017."},{"key":"2025120415064042000_15.10.e099559.16","first-page":"1","article-title":"Tuberculosis treatment non-adherence and lost to follow up among TB patients with or without HIV in developing countries: a systematic review","volume":"44","author":"Habteyes","year":"2015","journal-title":"Iran J Public Health"},{"key":"2025120415064042000_15.10.e099559.17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/09709274.2015.11906927","article-title":"Predictors of Non-adherence to Anti-Tuberculosis Medication in Tuberculosis Patients in Thailand","volume":"52","author":"Peltzer","year":"2015","journal-title":"J Hum Ecol"},{"key":"2025120415064042000_15.10.e099559.18","article-title":"Assessment of Anti-TB Drug Nonadherence and Associated Factors among TB Patients Attending TB Clinics in Arba Minch Governmental Health Institutions, Southern Ethiopia","volume":"2018","author":"Gube","year":"2018","journal-title":"Tuberc Res Treat"},{"key":"2025120415064042000_15.10.e099559.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-017-4188-9","article-title":"The prevalence and factors associated for anti-tuberculosis treatment non-adherence among pulmonary tuberculosis patients in public health care facilities in South Ethiopia: a cross-sectional study","volume":"17","author":"Woimo","year":"2017","journal-title":"BMC Public Health"},{"key":"2025120415064042000_15.10.e099559.20","doi-asserted-by":"crossref","DOI":"10.1186\/s13104-015-1452-x","article-title":"Adherence to Anti-tuberculosis treatment and treatment outcomes among tuberculosis patients in Alamata District, northeast Ethiopia","volume":"8","author":"Tesfahuneygn","year":"2015","journal-title":"BMC Res Notes"},{"key":"2025120415064042000_15.10.e099559.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-048945","article-title":"The relationship between mental health and risk of active tuberculosis: a systematic review","volume":"12","author":"Hayward","year":"2022","journal-title":"BMJ Open"},{"key":"2025120415064042000_15.10.e099559.22","doi-asserted-by":"publisher","DOI":"10.7861\/futurehosp.3-2-114"},{"key":"2025120415064042000_15.10.e099559.23","unstructured":"Coulter A , Roberts S , Dixon A . Delivering better services for people with long-term conditions. Building the house of care. London The King\u2019s Fund 2013;1\u201328."},{"key":"2025120415064042000_15.10.e099559.24","doi-asserted-by":"publisher","DOI":"10.1111\/hex.12640"},{"key":"2025120415064042000_15.10.e099559.25","unstructured":"World Health Organization . Tuberculosis: treatment success data by who income groups. 2019."},{"key":"2025120415064042000_15.10.e099559.26","first-page":"51","article-title":"Tuberculosis treatment outcomes and interruption among patients assessing DOTS regimen in a tertiary hospital in semi-urban area of south-western Nigeria","volume":"23","author":"Omotosho","year":"2014","journal-title":"Niger J Med"},{"key":"2025120415064042000_15.10.e099559.27","doi-asserted-by":"crossref","unstructured":"Karumbi J , Garner P . Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2015;2015. doi:10.1002\/14651858.CD003343.pub4","DOI":"10.1002\/14651858.CD003343.pub4"},{"key":"2025120415064042000_15.10.e099559.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002595","article-title":"Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies","volume":"15","author":"Alipanah","year":"2018","journal-title":"PLoS Med"},{"key":"2025120415064042000_15.10.e099559.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002884","article-title":"The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials","volume":"16","author":"Vernon","year":"2019","journal-title":"PLoS Med"},{"key":"2025120415064042000_15.10.e099559.30","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-13-782","article-title":"Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study","volume":"13","author":"Hirpa","year":"2013","journal-title":"BMC Public Health"},{"key":"2025120415064042000_15.10.e099559.31","first-page":"64","article-title":"Social Support, Treatment Adherence and Outcome among Hypertensive and Type 2 Diabetes Patients in Ambulatory Care Settings in southwestern Nigeria","volume":"51","author":"Adisa","year":"2017","journal-title":"Ghana Med J"},{"key":"2025120415064042000_15.10.e099559.32","unstructured":"World Health Organization . Global tuberculosis report 2019. Geneva, 2019."},{"key":"2025120415064042000_15.10.e099559.33","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1257\/aeri.20210515","article-title":"The Impact of Financial Assistance Programs on Health Care Utilization: Evidence from Kaiser Permanente","volume":"4","author":"Adams","year":"2022","journal-title":"Am Econ Rev Insights"},{"key":"2025120415064042000_15.10.e099559.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-036985","article-title":"Impacts of social support on the treatment outcomes of drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"10","author":"Wen","year":"2020","journal-title":"BMJ Open"},{"key":"2025120415064042000_15.10.e099559.35","doi-asserted-by":"crossref","DOI":"10.1186\/s12992-019-0459-9","article-title":"Perspectives on TB patients\u2019 care and support: a qualitative study conducted in Accra Metropolis, Ghana","volume":"15","author":"Gyimah","year":"2019","journal-title":"Global Health"},{"key":"2025120415064042000_15.10.e099559.36","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-021-10698-9","article-title":"Knowledge about tuberculosis, treatment adherence and outcome among ambulatory patients with drug-sensitive tuberculosis in two directly-observed treatment centres in Southwest Nigeria","volume":"21","author":"Adisa","year":"2021","journal-title":"BMC Public Health"},{"key":"2025120415064042000_15.10.e099559.37","unstructured":"World Health Organization . Tuberculosis: key facts 2021. Geneva, 2021."},{"key":"2025120415064042000_15.10.e099559.38","unstructured":"World health organization . Global tuberculosis report 2022. Geneva, 2022."},{"key":"2025120415064042000_15.10.e099559.39","unstructured":"World Health Organization . Implementing the end tb strategy: the essentials. Geneva, 2022."},{"key":"2025120415064042000_15.10.e099559.40","unstructured":"World Health Organization . Global tuberculosis report 2017. document who\/htm\/tb\/2017.23. Geneva, 2017. Available: https:\/\/apps.who.int\/iris\/bitstrea m\/10665\/259366\/1\/978924\/565516-eng.pdf>un=1 [accessed 15 Oct 2024]"},{"key":"2025120415064042000_15.10.e099559.41","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30703-X"},{"key":"2025120415064042000_15.10.e099559.42","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-024-11683-9","article-title":"Impact of pharmacist-led intervention in medication adherence and inhaler usage on asthma and chronic obstructive pulmonary disease control: a quasi-experimental study","volume":"24","author":"Adisa","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"2025120415064042000_15.10.e099559.43","unstructured":"Yamane T . Statistics: An Introductory Analysis. 2nd edn. New York: Harper and Row, 1967."},{"key":"2025120415064042000_15.10.e099559.44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4314\/ahs.v14i1.2","article-title":"Treatment non-adherence among patients with poorly controlled type 2 diabetes in ambulatory care settings in southwestern Nigeria","volume":"14","author":"Adisa","year":"2014","journal-title":"Afr Health Sci"},{"key":"2025120415064042000_15.10.e099559.45","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-018-0934-x","article-title":"Treatment adherence and blood pressure outcome among hypertensive out-patients in two tertiary hospitals in Sokoto, Northwestern Nigeria","volume":"18","author":"Adisa","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"2025120415064042000_15.10.e099559.46","doi-asserted-by":"crossref","unstructured":"Adisa R , Fakeye TO , Fasanmade AO . Medication adherence among ambulatory patients with type 2 diabetes in a tertiary healthcare setting in Southwestern Nigeria. Pharmacy Practice (Internet) 2011;9. doi:10.4321\/S1886-36552011000200003","DOI":"10.4321\/S1886-36552011000200003"},{"key":"2025120415064042000_15.10.e099559.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2025120415064042000_15.10.e099559.48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jiph.2016.11.018","article-title":"Factors contributing to non-adherence with treatment among TB patients in Sodo Woreda, Gurage Zone, Southern Ethiopia: A qualitative study","volume":"10","author":"Gugssa Boru","year":"2017","journal-title":"J Infect Public Health"},{"key":"2025120415064042000_15.10.e099559.49","article-title":"Tuberculosis Treatment Adherence of Patients in Kosovo","volume":"2017","author":"Krasniqi","year":"2017","journal-title":"Tuberc Res Treat"},{"key":"2025120415064042000_15.10.e099559.50","doi-asserted-by":"crossref","unstructured":"Bradshaw J , Siddiqui N , Greenfield D , et al . Kindness, Listening, and Connection: Patient and Clinician Key Requirements for Emotional Support in Chronic and Complex Care. J Patient Exp 2022;9. doi:10.1177\/23743735221092627","DOI":"10.1177\/23743735221092627"},{"key":"2025120415064042000_15.10.e099559.51","first-page":"e461","article-title":"Association between different types of social support and medication adherence","volume":"18","author":"Scheurer","year":"2012","journal-title":"Am J Manag Care"},{"key":"2025120415064042000_15.10.e099559.52","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1353\/hpu.2011.0083","article-title":"The role of social support in multiple morbidity: self-management among rural residents","volume":"22","author":"Bardach","year":"2011","journal-title":"J Health Care Poor Underserved"},{"key":"2025120415064042000_15.10.e099559.53","unstructured":"Taylor SE . Social support: a review. In: Friedman MS , ed. The Handbook of Health Psychology. New York, NY: Oxford University Press, n.d.: 189\u2013214."},{"key":"2025120415064042000_15.10.e099559.54","doi-asserted-by":"publisher","DOI":"10.1177\/014572170403000321"},{"key":"2025120415064042000_15.10.e099559.55","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0383"},{"key":"2025120415064042000_15.10.e099559.56","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-019-1014-8","article-title":"Medication adherence influencing factors-an (updated) overview of systematic reviews","volume":"8","author":"Gast","year":"2019","journal-title":"Syst Rev"},{"key":"2025120415064042000_15.10.e099559.57","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0814-7"},{"key":"2025120415064042000_15.10.e099559.58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jvn.2018.10.005","article-title":"Effect of social support on the treatment adherence of hypertension patients","volume":"37","author":"Turan","year":"2019","journal-title":"J Vasc Nurs"},{"key":"2025120415064042000_15.10.e099559.59","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.12659\/MSM.913510","article-title":"Prevalence of and Factors Influencing Anti-Tuberculosis Treatment Non-Adherence Among Patients with Pulmonary Tuberculosis: A Cross-Sectional Study in Anhui Province, Eastern China","volume":"25","author":"Fang","year":"2019","journal-title":"Med Sci Monit"},{"key":"2025120415064042000_15.10.e099559.60","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0181"},{"key":"2025120415064042000_15.10.e099559.61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/2224-3151.206624","article-title":"Innovative social protection mechanism for alleviating catastrophic expenses on multidrug-resistant tuberculosis patients in Chhattisgarh, India","volume":"4","author":"Kundu","year":"2015","journal-title":"WHO South-East Asia J Public Health"},{"key":"2025120415064042000_15.10.e099559.62","doi-asserted-by":"crossref","unstructured":"Hutchison C , Khan MS , Yoong J . Financial barriers and coping strategies: a qualitative study of accessing multidrug-resistant tuberculosis and tuberculosis care in Yunnan, China. BMC Public Health 2017;17. doi:10.1186\/s12889-017-4089-y","DOI":"10.1186\/s12889-017-4089-y"},{"key":"2025120415064042000_15.10.e099559.63","first-page":"250","article-title":"Coping Mechanisms","volume":"2","author":"Algorani","year":"2021","journal-title":"StatPearls Journal"},{"key":"2025120415064042000_15.10.e099559.64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219891","article-title":"Implementation of Medication Event Reminder Monitors among patients diagnosed with drug susceptible tuberculosis in rural Viet Nam: A qualitative study","volume":"14","author":"Drabarek","year":"2019","journal-title":"PLoS ONE"},{"key":"2025120415064042000_15.10.e099559.65","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00098-2018"},{"key":"2025120415064042000_15.10.e099559.66","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.ijid.2021.02.107","article-title":"Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts","volume":"113 Suppl 1","author":"Chakaya","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2025120415064042000_15.10.e099559.67","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S1473-3099(18)30654-6","article-title":"Global burden of tuberculosis: where we are and what to do","volume":"18","author":"Grobusch","year":"2018","journal-title":"Lancet Infect Dis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-099559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:10:16Z","timestamp":1764889816000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-099559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":67,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjopen-2025-099559"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-099559","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}